VBI Vaccines Announces New Tumor Response Data from Ongoing

Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response and two stable disease observations have occurred as of May 15,...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Massachusetts , United States , Canada , Israel , Rehovot , Hamerkaz , Ottawa , Ontario , Canadian , American , Prehevbrio Prehevbri , Brii Biosciences , Davide Anderson , Jeff Baxter , Company Quarterly Reports On Form , Nasdaq , American Society Of Clinical Oncology , Vaccines Inc , Oncology Center , Drug Administration , Clinical Oncology , Annual Meeting , Scientific Officer , Fast Track , Orphan Drug Designations , Data Poster Highlights , Study Arm , Granulocyte Macrophage Colony Stimulating Factor , Randomized Phase , Central Nervous System Tumors , Patient Enrollment , Study Design , Study Data Highlights , Track Designation , Orphan Drug Designation , Accelerated Approval , Priority Review , Drug Evaluation , Biologics Evaluation , Clinical Trial Endpoints , Cancer Drugs , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Quarterly Reports ,